Louis J. DeGennaro, Ph.D., was named president and chief executive officer of The Leukemia & Lymphoma Society (LLS) in September 2014 and now leads the operations of this $300 million cancer patient advocacy agency with headquarters in White Plains, New York.
A critical member of the LLS executive leadership team, he joined LLS in 2005 and was named chief mission officer in 2009, with responsibility for leadership of LLS’s mission functions of research, patient access, education, public policy and advocacy. Dr. DeGennaro is recognized as the key architect of LLS’s cures and access agenda to help save lives of blood cancer patients as well as the LLS Therapy Acceleration Program® - a venture philanthropy endeavor that defined the role of nonprofit organizations in supporting drug discovery and development with the biotechnology industry.
Dr. DeGennaro has more than 25 years of research, drug development and executive management experience in academic and private sector settings. He received his Ph.D. in biochemistry from the University of California at San Francisco and did his post-doctoral research at the Yale University School of Medicine. His previous academic appointments include research group leader, Max Planck Institute in Munich, Germany and associate professor of neurology and cell biology, University of Massachusetts Medical School. Dr. DeGennaro's private-sector positions include senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, NJ, and executive vice president for research and development, SynX Pharma, Inc. in Toronto, Canada.